Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares (ACUTE-GO)

9 de noviembre de 2026 actualizado por: ANI Pharmaceuticals

A Randomized, Multi-Center, Double-blind, Efficacy and Safety Study of Two Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares

The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.

Researchers will compare two different doses of Purified Cortrophin Gel.

Participants will:

  • Receive one injection of Purified Cortrophin Gel
  • Have 2 in-person visits to the site and 3 virtual/telephone visits
  • Complete daily surveys about their gout flare

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

160

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Reclutamiento
        • Mass General Hospital
        • Investigador principal:
          • Hyon K Choi, MD, DrPH
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 90 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Main inclusion criteria:

  1. Signed informed consent to participate in this study.

  2. Male and female patients, aged 18-90 years.

  3. Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.

  4. Onset of current acute gout flare within 5 days prior to study entry

  5. Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).

  6. History of ≥ 1 gout flares within the 12 months prior to study entry

  7. The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:

    1. Minimum of one episode of inadequate response to treatment.
    2. The investigator deems that the patient is either contraindicated or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
  8. Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.

Main exclusion criteria:

  1. Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.

  2. Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).

  3. Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.

  4. Patients with sensitivity to proteins derived from porcine sources.

  5. Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.

  6. Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.

  7. Polyarticular gouty arthritis flare currently active in more than 4 joints.

  8. Patients who have taken an investigational drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.

  9. Previous inclusion in this study.

  10. Patients currently receiving dialysis.

  11. Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.

  12. Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.

  13. Prior or current treatment with any ACTH product.

  14. Pregnant or nursing (lactating) women. Women of childbearing potential are required to be using an acceptable method of contraception.

    1. Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
    2. Acceptable methods of contraception are:

    i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)

  15. Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.

  16. Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor [TNF] inhibitors) within specified periods prior to randomization.

  17. Vaccination within 30 days prior to study enrollment and during the study period.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: 40 U Purified Cortrophin Gel

One injection of Purified Cortrophin Gel, 40 U

Comparador activo: 80 U Purified Cortrophin Gel

One injection of Purified Cortrophin Gel, 80 U

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in gout pain intensity from baseline in the target joint following PCG administration.
Periodo de tiempo: From baseline to Day 3

Change in gout pain intensity from baseline in the target joint following PCG administration measured by Visual Analog Scale (VAS) at 72 hours post-injection (Day 3) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain.

From baseline to Day 3

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured by Visual Analog Scale (VAS) at Day 1 (24 hours post-injection)
Periodo de tiempo: Baseline to Day 1

Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured at Day 1 (24 hours post-injection) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100

Baseline to Day 1
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured by Visual Analog Scale (VAS) at Day 2 (48 hours post-injection)
Periodo de tiempo: Baseline to Day 2

Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain.

Baseline to Day 2
Change in pain intensity timeline at baseline, 24 hours, 48 hours, 72 hours, and Day 7 post-injection
Periodo de tiempo: Baseline to Day 7
Baseline to Day 7
Time to onset of effect (≥20% change from baseline pain intensity on VAS)
Periodo de tiempo: Baseline to Day 7
Baseline to Day 7
Time to response (≥50% change from baseline pain intensity on VAS)
Periodo de tiempo: Baseline to Day 7
Baseline to Day 7
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale)
Periodo de tiempo: Baseline to Day 7

Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale) 24 hours, 48 hours, 72 hours, and Day 7 post-injection scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response.

Baseline to Day 7
Physician-Assessed Inflammatory Signs of the Index Joint (Joint Tenderness, Swelling, Range of Motion, and Erythema)
Periodo de tiempo: Baseline to Day 3

Investigator-assessed composite of inflammatory signs in the index (most affected) joint, evaluated at baseline (Day 0) and 72 hours post-injection (Day 3):

Joint tenderness - assessed via palpation/passive motion on a 4-point Likert scale: 0 (no pain) to 3 (severe/patient winces and withdraws); lower scores indicate better outcome.

Joint swelling - 4-point Likert scale: 0 (no swelling) to 3 (severe swelling/bulging beyond joint margins); lower scores indicate better outcome.

Target joint range of motion - 5-point Likert scale: 0 (normal) to 4 (immobilized); lower scores indicate better outcome.

Erythema - categorical assessment: present, absent, or not assessable.

Baseline to Day 3
Physician assessment of local tolerability at injection site (at 72 hours post-injection) - Number of Participants with Injection Site Reactions (Adverse Events)
Periodo de tiempo: Baseline to Day 3

Local tolerability at the injection site will be assessed via investigator-reported adverse events. Injection site reactions occurring after study drug administration will be captured. The AE will be graded based on severity: MILD/MODERATE/SEVERE and causality: related/not related to study drug.

Baseline to Day 3
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale)
Periodo de tiempo: Baseline to Day 3

Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response.

Baseline to Day 3
Use of rescue medication (up to 72-hours post-injection)
Periodo de tiempo: Baseline to Day 3
Baseline to Day 3
Safety and Tolerability Assessments (Adverse Events, Serious Adverse Events, Clinical Laboratory Parameters, and Vital Signs)
Periodo de tiempo: Baseline to Day 7

Safety will be assessed as follows:

Adverse Events (AEs) and Serious Adverse Events (SAEs) - collected from study drug administration through Day 7, graded by the investigator as MILD, MODERATE, or SEVERE, and assessed for causality (related/not related to study drug).

Clinical laboratory safety parameters - collected at baseline (Day 0) and Day 3, including biochemistry (AST, ALT, total bilirubin, ALP, PT/INR, albumin, total/LDL/HDL cholesterol, triglycerides, creatinine, sodium, potassium, ferritin, uric acid, glucose, HbA1c, troponin T, CRP, calcium, magnesium), hematology (hemoglobin, hematocrit, WBC with differential, platelets, ESR), and urinalysis (albumin, erythrocytes, hCG where applicable).

Vital signs - systolic and diastolic blood pressure (mmHg), heart rate (bpm), and body temperature (°F), collected at baseline (Day 0) and Day 3, following a 5-minute rest period.

Baseline to Day 7

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in Serum C-Reactive Protein (CRP) Level
Periodo de tiempo: Baseline to Day 3

Levels of C-reactive protein inflammatory markers (baseline [Day 0], 72 hours [Day 3]) continuous biomarker in mg/L (confirm units with your lab). Increasing CRP reflects worsening inflammation

Baseline to Day 3
Change from Baseline in Gout Attack Intensity Score (GAIS)
Periodo de tiempo: Baseline to Day 3

Change from baseline in health-related quality-of-life Gout Attack Intensity Score (GAIS) at Day 0 and at Day 3 (72-hours post-injection). GAIS is the mean of 3 patient-reported items (pain, tenderness, swelling), each scored 1-5; range 1-5, with higher scores indicating worse (more severe) gout attack intensity.

Baseline to Day 3

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de enero de 2026

Finalización primaria (Estimado)

30 de noviembre de 2027

Finalización del estudio (Estimado)

30 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ANI-PCG-003

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .